Targeting myeloid differentiation 2 for treatment of sepsis

Frontiers in Bioscience - Landmark

Volumn 19, Issue 6, 2014, Pages 906-915

  Duan, Guangjie ^a   Zhu, Jiang ^a   Xu, Jianhua ^a   Liu, Yousheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Eritoran; Lipopolysaccharide; Myeloid differentiation 2; Review; Sepsis; Toll like receptor 4

Indexed keywords

DISACCHARIDE; ERITORAN; LIPOPOLYSACCHARIDE; LY96 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN MD 2; SUGAR PHOSPHATE; TOLL LIKE RECEPTOR 4;

ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; SEPSIS; SIGNAL TRANSDUCTION;

DISACCHARIDES; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; SEPSIS; SIGNAL TRANSDUCTION; SUGAR PHOSPHATES; TOLL-LIKE RECEPTOR 4;

EID: 84904287365     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4256     Document Type: Review

References (65)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (4): 1250-6 (2003)
2. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest 101 (6): 1644-55 (1992)
3. Annane D, E Bellissant, JM Cavaillon: Septic shock. Lancet 365 (9453): 63-78 (2005)
4. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34 (1): 17-60 (2008)
5. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (16): 1546-54 (2003)
6. Xiao H, J Siddiqui, DG Remick: Mechanisms of mortality in early and late sepsis. Infect Immun 74 (9): 5227-35 (2006)
7. de Jong HK, T van der Poll, WJ Wiersinga: The systemic pro-inflammatory response in sepsis. J Innate Immun2 (5): 422-30 (2010)
8. Kumpf O, RR Schumann: Genetic variation in innate immunity pathways and their potential contribution to the SIRS/CARS debate: evidence from human studies and animal models. J Innate Immun 2 (5): 381-94 (2010)
9. Hotchkiss RS, et al: The sepsis seesaw: tilting toward immunosuppression. Nat Med 15 (5): 496-7 (2009)
10. Schroder K, J Tschopp: The inflammasomes. Cell 140 (6): 821-32 (2010)
11. Kawai T, S Akira: The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11 (5): 373-84 (2010)
12. van der Poll T, SM Opal: Host-pathogen interactions in sepsis. Lancet Infect Dis 8 (1): 32-43 (2008)
13. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 190 (3): 527-34 (2004)
14. Davies B, J Cohen: Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 11 (1): 65-71 (2011)
15. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189 (11): 1777-82 (1999)
16. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S: Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3 (7): 667-72 (2002)
17. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A: Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 6 (6): 571-8 (2005)
18. Nagai Y, Shimazu R, Ogata H, Akashi S, Sudo K, Yamasaki H: Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood 99 (5): 1699-705 (2002)
19. Visintin A, Mazzoni A, Spitzer JA, Segal DM: Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci U S A 98 (21): 12156-61 (2001)
20. Rallabhandi P, Bell J, Boukhvalova MS, Medvedev A, Lorenz E, Arditi M: Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 177 (1): 322-32 (2006)
21. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC: Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130 (5): 906-17 (2007)
22. Hyakushima N, Mitsuzawa H, Nishitani C, Sano H, Kuronuma K, Konishi M: Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling. J Immunol 173 (11): 6949-54 (2004)
23. Nishitani C, Mitsuzawa H, Hyakushima N, Sano H, Matsushima N, Kuroki Y: The Toll-like receptor 4 region Glu24-Pro34 is critical for interaction with MD-2. Biochem Biophys Res Commun 328 (2): 586-90 (2005)
24. Nishitani C, Mitsuzawa H, Sano H, Shimizu T, Matsushima N, Kuroki Y: Toll-like receptor 4 region Glu24-Lys47 is a site for MD-2 binding: importance of CYS29 and CYS40. J Biol Chem 281 (50): 38322-9 (2006)
25. Re F, Strominger JL: Separate functional domains of human MD-2 mediate Toll-like receptor 4-binding and lipopolysaccharide responsiveness. J Immunol 171 (10): 5272-6 (2003)
26. Kang JY, Lee JO: Structural biology of the Toll-like receptor family. Annu Rev Biochem 80: 917-41 (2011)
27. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO: The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458 (7242): 1191-5 (2009)
28. Resman N, Vasl J, Oblak A, Pristovsek P, Gioannini TL, Weiss JP: Essential roles of hydrophobic residues in both MD-2 and toll-like receptor 4 in activation by endotoxin. J Biol Chem 284 (22): 15052-60 (2009)
29. Gangloff M, AN Weber, NJ Gay: Conserved mechanisms of signal transduction by Toll and Toll-like receptors. J Endotoxin Res 11 (5): p294-8 (2005)
30. Miyake, K: Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res12 (4): 195-204 (2006)
31. Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT: Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 175 (10): 6465-72 (2005)
32. Ohta S, Bahrun U, Tanaka M, Kimoto M: Identification of a novel isoform of MD-2 that downregulates lipopolysaccharide signaling. Biochem Biophys Res Commun 323 (3): 1103-8 (2004)
33. Miao HL, Qiu ZD, Hao FL, Bi YH, Li MY, Chen M: Significance of MD-2 and MD-2B expression in rat liver during acute cholangitis. World J Hepatol 2 (6): 233-8 (2010)
34. Ohnishi T, M. Muroi, and K. Tanamoto: MD-2 is necessary for the toll-like receptor 4 protein to undergo glycosylation essential for its translocation to the cell surface. Clin Diagn Lab Immunol 10 (3): 405-10 (2003)
35. Nishitani C, Takahashi M, Mitsuzawa H, Shimizu T, Ariki S, Matsushima N: Mutational analysis of Cys (88) of Toll-like receptor 4 highlights the critical role of MD-2 in cell surface receptor expression. Int Immunol 21 (8): 925-34 (2009)
36. Tsukamoto H, Ihara H, Ito R, Ukai I, Suzuki N, Kimoto M: MD-2-dependent human Toll-like receptor 4 monoclonal antibodies detect extracellular association of Toll-like receptor 4 with extrinsic soluble MD-2 on the cell surface. Biochem Biophys Res Commun 440 (1): 31-6 (2013)
37. Wakabayashi Y, Kobayashi M, Akashi-Takamura S, Tanimura N, Konno K, Takahashi K: A protein associated with toll-like receptor 4 (PRAT4A) regulates cell surface expression of TLR4. J Immunol 177 (3): 1772-9 (2006)
38. Park JE, YI Kim, Yi AK: Protein kinase D1 is essential for MyD88-dependent TLR signaling pathway. J Immunol 182 (10): 6316-27 (2009)
39. Park SH, Kim ND, Jung JK, Lee CK, Han SB, Kim Y: Myeloid differentiation 2 as a therapeutic target of inflammatory disorders. Pharmacol Ther 133 (3): 291-8 (2012)
40. O'Neill LA, Bowie AG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7 (5): 353-64 (2007)
41. Keating SE, Maloney GM, Moran EM, Bowie AG.: IRAK-2 participates in multiple toll-like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. J Biol Chem 282 (46): 33435-43 (2007)
42. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y: Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol9 (6): 684-91 (2008)
43. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO: Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424 (6950): 743-8 (2003)
44. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H: Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301 (5633): 640-3 (2003)
45. Jiang Z, Zamanian-Daryoush M, Nie H, Silva AM, Williams BR, Li X: Poly (I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem 278 (19): 16713-9 (2003)
46. Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M: RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 5 (5): 503-7 (2004)
47. Oganesyan G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B: Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439 (7073): 208-11 (2006)
48. Hadina S, Weiss JP, McCray PB Jr, Kulhankova K, Thorne PS: MD-2-dependent pulmonary immune responses to inhaled lipooligosaccharides: effect of acylation state. Am J Respir Cell Mol Biol 38 (6): 647-54 (2008)
49. Pugin J, Stern-Voeffray S, Daubeuf B, Matthay MA, Elson G, Dunn-Siegrist I: Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 104 (13): 4071-9 (2004)
50. Akashi S, Nagai Y, Ogata H, Oikawa M, Fukase K, Kusumoto S: Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol13 (12): 1595-9 (2001)
51. Muroi, M. and K. Tanamoto: Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa. J Biol Chem281 (9): 5484-91 (2006)
52. Saitoh S, Akashi S, Yamada T, Tanimura N, Matsumoto F: Ligand-dependent Toll-like receptor 4 (TLR4)-oligomerization is directly linked with TLR4-signaling. J Endotoxin Res 10 (4): 257-60 (2004)
53. Meng J, Drolet JR, Monks BG, Golenbock DT: MD-2 residues tyrosine 42, arginine 69, aspartic acid 122, and leucine 125 provide species specificity for lipid IVA. J Biol Chem 285 (36): 27935-43 (2010)
54. Ohto U, Fukase K, Miyake K, Shimizu T: Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc Natl Acad Sci U S A 109 (19): 7421-6 (2012)
55. Artner D, Oblak A, Ittig S, Garate JA, Horvat S, Arrieumerlou C: Conformationally Constrained Lipid A Mimetics for Exploration of Structural Basis of TLR4/MD-2 Activation by Lipopolysaccharide. ACS Chem Biol 8 (11):2423-32. (2013)
56. Hawkins, L.D., W.J. Christ, and D.P. Rossignol: Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 4 (11): 1147-71. (2004)
57. Barochia A, Solomon S, Cui X, Natanson C, Eichacker PQ: Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxico 7 (4): 479-94 l (2011)
58. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R: Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 38 (1): 72-83 (2010)
59. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309 (11): 1154-62 (2013)
60. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A: Inhibition of TLR-4/MD-2 signaling by RP105/MD-1. J Endotoxin Res 11 (6): 363-8 (2005)
61. Liu B, Fu Y, Feng S, Zhang X, Liu Z, Cao Y: Involvement of RP105 and toll-like receptors in the activation of mouse peritoneal macrophages by Staphylococcus aureus. Scand J Immunol 78 (1): 8-16 (2013)
62. Kondo Y, et al :TLR4-MD-2 complex is negatively regulated by an endogenous ligand, globotetraosylceramide. Proc Natl Acad Sci U S A 110 (12): 4714-9 (2013)
63. Kondo Y, Ikeda K, Tokuda N, Nishitani C, Ohto U, Akashi-Takamura S: Sulforaphane inhibits the engagement of LPS with TLR4/MD2 complex by preferential binding to Cys133 in MD2. Biochem Biophys Res Commun434 (3): 600-5 (2013)
64. Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y: Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 165 (12): 6682-6 (2000)
65. Mitsuzawa H, Nishitani C, Hyakushima N, Shimizu T, Sano H: Recombinant soluble forms of extracellular TLR4 domain and MD-2 inhibit lipopolysaccharide binding on cell surface and dampen lipopolysaccharide-induced pulmonary inflammation in mice. J Immunol 177 (11): 8133-9 (2006)